Skip to main content
. 2022 Oct 18;12:978069. doi: 10.3389/fonc.2022.978069

Figure 3.

Figure 3

Forest plot of hazard ratios for OS according to liver metastases in non-small cell lung cancer and small cell lung cancer patients.(A), Hazard Ratios for OS when comparing immunotherapy to control treatment.(B), The interaction between OS benefit of immunotherapy and liver metastases.